Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications

References

• Gluckman E, Broxmeyer HE, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. New England J Med. 1989;321:1174–1178.
   PubMed Web of Science ®Google Scholar
• Broxmeyer HE, Douglas GW, Hangoc G, et al Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci U S A. 1989;86:3828–3832.
   PubMed Web of Science ®Google Scholar
• Wagner JE, Broxmeyer HE, Byrd RL, et al. Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraftment. Blood. 1992;79:1874–1881.
   PubMed Web of Science ®Google Scholar
• Wagner JE, Rosenthal J, Sweetman R, et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood. 1996;88(3):795–802.
   PubMed Web of Science ®Google Scholar
• Laporte JP, Gorin NC, Rubinstein P, et al. Cord-blood transplantation from an unrelated donor in an adult with chronic myelogenous leukemia. New England J Med. 1996;335(3):167–170.
   PubMed Web of Science ®Google Scholar
• Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013;122(4):491–498.
   PubMed Web of Science ®Google Scholar
• Garderet L, Dulphy N, Douay C, et al. The umbilical cord blood alphabeta T-cell repertoire: characteristics of a polyclonal and naive but completely formed repertoire. Blood. 1998;91(1):340–346.
   PubMed Web of Science ®Google Scholar
• Stanevsky A, Goldstein G, Nagler A. Umbilical cord blood transplantation: pros, cons and beyond. Blood Rev. 2009;23(5):199–204.
   PubMed Web of Science ®Google Scholar
• Gammaitoni L, Weisel KC, Gunetti M, et al. Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replication. Blood. 2004;103(12):4440–4448.
   PubMed Web of Science ®Google Scholar
• Stanevsky A, Shimoni A, Yerushalmi R, et al. Cord blood stem cells for hematopoietic transplantation. Stem Cell Reviews. 2011;7(2):425–433.
   PubMed Web of Science ®Google Scholar
• Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood. 2001;97(10):2962–2971.
   PubMed Web of Science ®Google Scholar
• Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. New England J Med. 2004;351(22):2265–2275.
   PubMed Web of Science ®Google Scholar
• Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. New England J Med. 2004;351(22):2276–2285.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Ooi J, Tomonari A, et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood. 2007;109(3):1322–1330.
   PubMed Web of Science ®Google Scholar
• Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11(7):653–660.
   PubMed Web of Science ®Google Scholar
• Terakura S, Atsuta Y, Tsukada N, et al. Comparison of outcomes of 8/8 and 7/8 allele-matched unrelated bone marrow transplantation and single-unit cord blood transplantation in adults with acute leukemia. Biol Blood Marrow Transplantation: J Am Soc Blood Marrow Transplantation. 2015. doi:10.1016/j.bbmt.2015.10.006
   Google Scholar
• Ruggeri A, Labopin M, Sanz G, et al. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. Leukemia. 2015;29(9):1891–1900.
   PubMed Web of Science ®Google Scholar
• Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. New England J Med. 2001;344(24):1815–1822.
   PubMed Web of Science ®Google Scholar
• Gluckman E, Rocha V. Donor selection for unrelated cord blood transplants. Curr Opin Immunol. 2006;18(5):565–570.
   PubMed Web of Science ®Google Scholar
• Rodrigues CA, Sanz G, Brunstein CG, et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol: Official J Am Soc Clin Oncol. 2009;27(2):256–263.
   PubMed Web of Science ®Google Scholar
• Cohen YC, Scaradavou A, Stevens CE, et al. Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries. Bone Marrow Transplant. 2011;46(1):70–76.
   PubMed Web of Science ®Google Scholar
• Baron F, Labopin M, Ruggeri A, et al. Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood-a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation. J Hematol Oncol. 2015;8(1):107.
   PubMed Web of Science ®Google Scholar
• Horwitz ME, Frassoni F. Improving the outcome of umbilical cord blood transplantation through ex vivo expansion or graft manipulation. Cytotherapy. 2015;17(6):730–738.
   PubMed Web of Science ®Google Scholar
• Lund TC, Boitano AE, Delaney CS, et al. Advances in umbilical cord blood manipulation-from niche to bedside. Nat Rev Clin Oncol. 2015;12(3):163–174.
   PubMed Web of Science ®Google Scholar
• Pineault N, Abu-Khader A. Advances in umbilical cord blood stem cell expansion and clinical translation. Exp Hematol. 2015;43(7):498–513.
   PubMed Web of Science ®Google Scholar
• Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol. 1977;91:335–344.
   PubMed Web of Science ®Google Scholar
• Dexter TM, Moore MA, Sheridan AP. Maintenance of hemopoietic stem cells and production of differentiated progeny in allogeneic and semiallogeneic bone marrow chimeras in vitro. J Exp Med. 1977;145(6):1612–1616.
   PubMed Web of Science ®Google Scholar
• Breems DA, Blokland EA, Siebel KE, et al. Stroma-contact prevents loss of hematopoietic stem cell quality during ex vivo expansion of CD34+ mobilized peripheral blood stem cells. Blood. 1998;91(1):111–117.
   PubMed Web of Science ®Google Scholar
• McNiece I, Harrington J, Turney J, et al. Ex vivo expansion of cord blood mononuclear cells on mesenchymal stem cells. Cytotherapy. 2004;6(4):311–317.
   PubMed Web of Science ®Google Scholar
• Piacibello W, Sanavio F, Garetto L, et al. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood. 1997;89(8):2644–2653.
   PubMed Web of Science ®Google Scholar
• Conneally E, Cashman J, Petzer A, et al. Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice. Proc Natl Acad Sci U S A. 1997;94(18):9836–9841.
   PubMed Web of Science ®Google Scholar
• Piacibello W, Sanavio F, Severino A, et al. Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells. Blood. 1999;93(11):3736–3749.
   PubMed Web of Science ®Google Scholar
• Hogan CJ, Shpall EJ, McNulty O, et al. Engraftment and development of human CD34(+)-enriched cells from umbilical cord blood in NOD/LtSz-scid/scid mice. Blood. 1997;90(1):85–96.
   PubMed Web of Science ®Google Scholar
• Lazzari L, Lucchi S, Rebulla P, et al. Long-term expansion and maintenance of cord blood haematopoietic stem cells using thrombopoietin, Flt3-ligand, interleukin (IL)-6 and IL-11 in a serum-free and stroma-free culture system. Br J Haematol. 2001;112(2):397–404.
   PubMed Web of Science ®Google Scholar
• McNiece I, Jones R, Bearman SI, et al. Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer. Blood. 2000;96(9):3001–3007.
   PubMed Web of Science ®Google Scholar
• Shpall EJ, Quinones R, Giller R, et al. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant. 2002;8(7):368–376.
   PubMed Web of Science ®Google Scholar
• Jaroscak J, Goltry K, Smith A, et al. Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell System. Blood. 2003;101(12):5061–5067.
   PubMed Web of Science ®Google Scholar
• De Lima M, McMannis J, Gee A, et al. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant. 2008;41(9):771–778.
   PubMed Web of Science ®Google Scholar
• Delaney C, Heimfeld S, Brashem-Stein C, et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med. 2010;16(2):232–236.
   PubMed Web of Science ®Google Scholar
• Delaney C, Bollard CM, Shpall EJ. Cord blood graft engineering. Biol Blood Marrow Transplantation: J Am Soc Blood Marrow Transplantation. 2013;19(1 Suppl):S74–78.
   PubMed Web of Science ®Google Scholar
• De Lima M, McNiece I, Robinson SN, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. New England J Med. 2012;367(24):2305–2315.
   PubMed Web of Science ®Google Scholar
• Horwitz ME, Chao NJ, Rizzieri DA, et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Investig. 2014;124(7):3121–3128.
   PubMed Web of Science ®Google Scholar
• Wagner JE, Brunstein C, McKenna D, et al. StemRegenin-1 (SR1) Expansion culture abrogates the engraftment barrier associated with umbilical cord blood transplantation (UCBT). Blood. 2014;124(21):728–728.
   PubMed Web of Science ®Google Scholar
• Cutler C, Multani P, Robbins D, et al. Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood. 2013;122(17):3074–3081.
   PubMed Web of Science ®Google Scholar
• Popat U, Mehta RS, Rezvani K, et al. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015;125(19):2885–2892.
   PubMed Web of Science ®Google Scholar
• Peled T, Landau E, Mandel J, et al. Linear polyamine copper chelator tetraethylenepentamine augments long-term ex vivo expansion of cord blood-derived CD34+ cells and increases their engraftment potential in NOD/SCID mice. Exp Hematol. 2004;32(6):547–555.
   PubMed Web of Science ®Google Scholar
• Barker JN, Weisdorf DJ, Wagner JE. Creation of a double chimera after the transplantation of umbilical-cord blood from two partially matched unrelated donors. New England J Med. 2001;344(24):1870–1871.
   PubMed Web of Science ®Google Scholar
• Barker JN, Weisdorf DJ, Defor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005;105(3):1343–1347.
   PubMed Web of Science ®Google Scholar
• Stanevsky A, Shimoni A, Yerushalmi R, et al. Double umbilical cord blood transplant: more than a cell dose? Leuk Lymphoma. 2010;51(6):975–982.
   PubMed Web of Science ®Google Scholar
• Haspel RL, Kao G, Yeap BY, et al. Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation. Bone Marrow Transplant. 2008;41(6):523–529.
   PubMed Web of Science ®Google Scholar
• Ramirez P, Wagner JE, DeFor TE, et al. Factors predicting single-unit predominance after double umbilical cord blood transplantation. Bone Marrow Transplant. 2012;47(6):799–803.
   PubMed Web of Science ®Google Scholar
• Scaradavou A, Brunstein CG, Eapen M, et al. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood. 2013;121(5):752–758.
   PubMed Web of Science ®Google Scholar
• Ruggeri A, Sanz G, Bittencourt H, et al. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. Leukemia. 2014;28(4):779–786.
   PubMed Web of Science ®Google Scholar
• Wagner JE Jr., Eapen M, Carter S, et al. One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med. 2014;371(18):1685–1694.
   PubMed Web of Science ®Google Scholar
• Kogler G, Nurnberger W, Fischer J, et al. Simultaneous cord blood transplantation of ex vivo expanded together with non-expanded cells for high risk leukemia. Bone Marrow Transplant. 1999;24(4):397–403.
   PubMed Web of Science ®Google Scholar
• Sorrentino BP. Clinical strategies for expansion of haematopoietic stem cells (Review). Nat Rev Immunol. 2004;4(11):878–888.
   PubMed Web of Science ®Google Scholar
• MacDonald HR, Wilson A, Radtke F. Notch1 and T-cell development: insights from conditional knockout mice. Trends Immunol. 2001;22(3):155–160.
   PubMed Web of Science ®Google Scholar
• Stier S, Cheng T, Dombkowski D, et al. Notch1 activation increases hematopoietic stem cell self-renewal in vivo and favors lymphoid over myeloid lineage outcome. Blood. 2002;99(7):2369–2378.
   PubMed Web of Science ®Google Scholar
• Ohishi K, Varnum-Finney B, Bernstein ID. Delta-1 enhances marrow and thymus repopulating ability of human CD34 + CD38 - cord blood cells. J Clin Investig. 2002;110(8):1165–1174.
   PubMed Web of Science ®Google Scholar
• Karanu FN, Murdoch B, Gallacher L, et al. The notch ligand jagged-1 represents a novel growth factor of human hematopoietic stem cells. J Exp Med. 2000;192(9):1365–1372.
   PubMed Web of Science ®Google Scholar
• Dallas MH, Varnum-Finney B, Delaney C, et al. Density of the Notch ligand Delta1 determines generation of B and T cell precursors from hematopoietic stem cells. J Exp Med. 2005;201(9):1361–1366.
   PubMed Web of Science ®Google Scholar
• Dominici M, Le BK, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–317.
   PubMed Web of Science ®Google Scholar
• Friedenstein AJ, Petrakova KV, Kurolesova AI, et al. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968;6(2):230–247.
   PubMed Web of Science ®Google Scholar
• Briquet A, Dubois S, Bekaert S, et al. Prolonged ex vivo culture of human bone marrow mesenchymal stem cells influences their supportive activity toward NOD/SCID-repopulating cells and committed progenitor cells of B lymphoid and myeloid lineages. Haematologica. 2010;95(1):47–56.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371(9624):1579–1586.
   PubMed Web of Science ®Google Scholar
• Bruck F, Belle L, Lechanteur C, et al. Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease. Cytotherapy. 2013;15(3):267–279.
   PubMed Web of Science ®Google Scholar
• Baron F, Storb R. Mesenchymal stromal cells: a new tool against graft-versus-host disease? Biol.Blood Marrow Transplant. 2012;18(6):822–840.
   PubMed Web of Science ®Google Scholar
• Robinson SN, Ng J, Niu T, et al. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant. 2006;37(4):359–366.
   PubMed Web of Science ®Google Scholar
• Peled T, Shoham H, Aschengrau D, et al. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment. Exp Hematol. 2012;40(4):342–355.
   PubMed Web of Science ®Google Scholar
• Boitano AE, Wang J, Romeo R, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science. 2010;329(5997):1345–1348.
   PubMed Web of Science ®Google Scholar
• Fares I, Chagraoui J, Gareau Y, et al. Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. Science. 2014;345(6203):1509–1512.
   PubMed Web of Science ®Google Scholar
• Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 1999;283(5403):845–848.
   PubMed Web of Science ®Google Scholar
• Heazlewood SY, Oteiza A, Cao H, et al. Analyzing hematopoietic stem cell homing, lodgment, and engraftment to better understand the bone marrow niche. Ann N Y Acad Sci. 2014;1310:119–128.
   PubMed Web of Science ®Google Scholar
• Frassoni F, Gualandi F, Podesta M, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol. 2008;9(9):831–839.
   PubMed Web of Science ®Google Scholar
• Rocha V, Labopin M, Ruggeri A, et al. Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies. Transplantation. 2013;95(10):1284–1291.
   PubMed Web of Science ®Google Scholar
• Christopherson KW 2nd, Hangoc G, Broxmeyer HE. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J Immunol. 2002;169(12):7000–7008.
   PubMed Web of Science ®Google Scholar
• Christopherson KW 2nd, Paganessi LA, Napier S, et al. CD26 inhibition on CD34+ or lineage- human umbilical cord blood donor hematopoietic stem cells/hematopoietic progenitor cells improves long-term engraftment into NOD/SCID/Beta2null immunodeficient mice. Stem Cells Dev. 2007;16(3):355–360.
   PubMed Web of Science ®Google Scholar
• Farag SS, Srivastava S, Messina-Graham S, et al. In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev. 2013;22(7):1007–1015.
   PubMed Web of Science ®Google Scholar
• Brunstein CG, McKenna DH, DeFor TE, et al. Complement fragment 3a priming of umbilical cord blood progenitors: safety profile. Biol Blood Marrow Transplantation: J Am Soc Blood Marrow Transplantation. 2013;19(10):1474–1479.
   PubMed Web of Science ®Google Scholar
• Goessling W, Allen RS, Guan X, et al. Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Cell Stem Cell. 2011;8(4):445–458.
   PubMed Web of Science ®Google Scholar
• Hoggatt J, Singh P, Sampath J, et al. Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood. 2009;113(22):5444–5455.
   PubMed Web of Science ®Google Scholar
• Hidalgo A, Weiss LA, Frenette PS. Functional selectin ligands mediating human CD34(+) cell interactions with bone marrow endothelium are enhanced postnatally. J Clin Investig. 2002;110(4):559–569.
   PubMed Web of Science ®Google Scholar
• Xia L, McDaniel JM, Yago T, et al. Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow. Blood. 2004;104(10):3091–3096.
   PubMed Web of Science ®Google Scholar
• Hidalgo A, Frenette PS. Enforced fucosylation of neonatal CD34+ cells generates selectin ligands that enhance the initial interactions with microvessels but not homing to bone marrow. Blood. 2005;105(2):567–575.
   PubMed Web of Science ®Google Scholar
• Zhang X, Mozeleski B, Lemoine S, et al. CD4 T cells with effector memory phenotype and function develop in the sterile environment of the fetus. Sci Translational Med. 2014;6(238):238ra272.
   Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–733.
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra138.
   Web of Science ®Google Scholar
• Lynn RC, Poussin M, Kalota A, et al. Targeting of folate receptor beta on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Blood. 2015;125(22):3466–3476.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. Trends Immunol. 2015;36(8):494–502.
   PubMed Web of Science ®Google Scholar
• Singh H, Figliola MJ, Dawson MJ, et al. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using sleeping beauty system and artificial antigen presenting cells. Plos One. 2013;8(5):e64138.
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Huls H, Singh H, et al. Adoptive immunotherapy following umbilical cord blood transplantation using the sleeping beauty system and artificial antigen presenting cells to generate donor-derived T cells expressing a CD19-specific chimeric antigen receptor. Blood. 2013;122(21):4208–4208.
   Web of Science ®Google Scholar
• Pegram HJ, Purdon TJ, Van Leeuwen DG, et al. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia. 2015;29(2):415–422.
   PubMed Web of Science ®Google Scholar
• Berger C, Jensen MC, Lansdorp PM, et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Investig. 2008;118(1):294–305.
   PubMed Web of Science ®Google Scholar
• Sommermeyer D, Hudecek M, Kosasih PL, et al. Chimeric antigen receptor-modified T cells derived from defined CD8 and CD4 subsets confer superior antitumor reactivity in vivo. Leukemia. 2015. doi:10.1038/leu.2015.247
   PubMedGoogle Scholar
• Baron F, Turhan AG, Giron-Michel J, et al. Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood. 2002;99(6):2107–2113.
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097–2100.
   PubMed Web of Science ®Google Scholar
• Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102(3):814–819.
   PubMed Web of Science ®Google Scholar
• Baron F, Petersdorf EW, Sandmaier BM, et al. What is the role for donor NK cells after nonmyeloablative conditioning?. Blood. 2007;110(11):476. Abstract
   Google Scholar
• Willemze R, Rodrigues CA, Labopin M, et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia. 2009;23(3):492–500.
   PubMed Web of Science ®Google Scholar
• Cichocki F, Cooley S, Davis Z, et al. CD56CD57NKG2C NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. Leukemia. 2015. doi:10.1038/leu.2015.260
   PubMedGoogle Scholar
• Condiotti R, Zakai YB, Barak V, et al. Ex vivo expansion of CD56+ cytotoxic cells from human umbilical cord blood. Exp Hematol. 2001;29(1):104–113.
   PubMed Web of Science ®Google Scholar
• Vasu S, Berg M, Davidson-Moncada J, et al. A novel method to expand large numbers of CD56(+) natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation. Cytotherapy. 2015;17(11):1582–1593.
   PubMed Web of Science ®Google Scholar
• Saliba RM, Rezvani K, Leen A, et al. General and virus-specific immune cell reconstitution after double cord blood transplantation. Biol Blood Marrow Transplantation: J Am Soc Blood Marrow Transplantation. 2015;21(7):1284–1290.
   PubMed Web of Science ®Google Scholar
• Bosch M, Dhadda M, Hoegh-Petersen M, et al. Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy. 2012;14(10):1258–1275.
   PubMed Web of Science ®Google Scholar
• Hannon M, Beguin Y, Ehx G, et al. Immune recovery after allogeneic hematopoietic stem cell transplantation following flu-TBI versus TLI-ATG conditioning. Clinical Cancer Research: An Official J Am Assoc Cancer Research. 2015;21(14):3131–3139.
   PubMed Web of Science ®Google Scholar
• Pascal L, Mohty M, Ruggeri A, et al. Impact of rabbit ATG-containing myeloablative conditioning regimens on the outcome of patients undergoing unrelated single-unit cord blood transplantation for hematological malignancies. Bone Marrow Transplant. 2015;50(1):45–50.
   PubMed Web of Science ®Google Scholar
• Hanley PJ, Cruz CR, Savoldo B, et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009;114(9):1958–1967.
   PubMed Web of Science ®Google Scholar
• Micklethwaite KP, Savoldo B, Hanley PJ, et al. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010;115(13):2695–2703.
   PubMed Web of Science ®Google Scholar
• Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014;6(242):242ra283.
   Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3):1151–1164.
   PubMed Web of Science ®Google Scholar
• Liston A, Gray DH. Homeostatic control of regulatory T cell diversity. Nat Rev Immunol. 2014;14(3):154–165.
   PubMed Web of Science ®Google Scholar
• Ehx G, Hannon M, Beguin Y, et al. Validation of a multicolor staining to monitor phosphoSTAT5 levels in regulatory T-cell subsets. Oncotarget. 2016. doi:10.18632/oncotarget.6486
   Google Scholar
• Matsuoka K, Koreth J, Kim HT, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5(179):179ra143.
   Web of Science ®Google Scholar
• Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9(9):1144–1150.
   PubMed Web of Science ®Google Scholar
• Hannon M, Lechanteur C, Lucas S, et al. Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease. Transfusion. 2014;54(2):353–363.
   PubMed Web of Science ®Google Scholar
• Hippen KL, Merkel SC, Schirm DK, et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med. 2011;3(83):83ra41.
   PubMed Web of Science ®Google Scholar
• Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117(3):1061–1070.
   PubMed Web of Science ®Google Scholar
• Passweg JR, Baldomero H, Bader P, et al Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant. 2015;50(4):476–482.
   PubMed Web of Science ®Google Scholar